Evotec (EVO) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed Evotec (EVO) over the past year, gaining 119.7% versus a loss of 55.6%. Over five years, STTK leads with a -52.0% price change compared with -94.4% for EVO. Evotec is the larger company by market cap ($469.1 million vs $454.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | STTK |
|---|---|---|
| Share price | $1.32 | $4.46 |
| Market cap | $469.11M | $454.22M |
| 1-day change | -8.97% | -1.98% |
| YTD return | -57.14% | +22.19% |
| 1-year return | -55.56% | +119.70% |
| 5-year return | -94.44% | -51.99% |
| EPS (TTM) | $-0.59 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.00M |
| Revenue growth (YoY) | — | -82.52% |
| Net income (latest FY) | — | $-48.81M |
| Operating margin | — | -5150.80% |
| Net margin | — | -4880.90% |
| 52-week high | $3.87 | $8.33 |
| 52-week low | $1.32 | $1.93 |
| Distance from 52-week high | -65.89% | -46.46% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +237.12% | +245.29% |
| Average volume | 109.16K | 1.20M |
| Shares outstanding | 355.39M | 101.84M |
| Employees | 4,379 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed EVO by 175.3 percentage points over the past year.
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
EVO vs STTK FAQ
Which is bigger, Evotec or Shattuck Labs?
Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $454.22M for Shattuck Labs (STTK).
Which stock has performed better over the past year, EVO or STTK?
STTK returned +119.70% over the past 12 months, compared with -55.56% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Evotec and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.